These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 25975815)

  • 21. The potential of Sutherlandia frutescens for herb-drug interaction.
    Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
    Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
    Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
    Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.
    Durmus S; Lozano-Mena G; van Esch A; Wagenaar E; van Tellingen O; Schinkel AH
    Mol Pharm; 2015 Dec; 12(12):4259-69. PubMed ID: 26474710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
    Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
    Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions.
    Izumi S; Nozaki Y; Maeda K; Komori T; Takenaka O; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2015 Feb; 43(2):235-47. PubMed ID: 25414411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
    Noé J; Portmann R; Brun ME; Funk C
    Drug Metab Dispos; 2007 Aug; 35(8):1308-14. PubMed ID: 17470528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide.
    Varma MV; Lin J; Bi YA; Kimoto E; Rodrigues AD
    Drug Metab Dispos; 2015 Jul; 43(7):1108-18. PubMed ID: 25941268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does simvastatin cause more myotoxicity compared with other statins?
    Backes JM; Howard PA; Ruisinger JF; Moriarty PM
    Ann Pharmacother; 2009 Dec; 43(12):2012-20. PubMed ID: 19920157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast.
    Varma MV; Kimoto E; Scialis R; Bi Y; Lin J; Eng H; Kalgutkar AS; El-Kattan AF; Rodrigues AD; Tremaine LM
    Clin Pharmacol Ther; 2017 Mar; 101(3):406-415. PubMed ID: 27648490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of hepatic organic anion-transporting polypeptide by RNA interference in sandwich-cultured human hepatocytes: an in vitro model to assess transporter-mediated drug-drug interactions.
    Liao M; Raczynski AR; Chen M; Chuang BC; Zhu Q; Shipman R; Morrison J; Lee D; Lee FW; Balani SK; Xia CQ
    Drug Metab Dispos; 2010 Sep; 38(9):1612-22. PubMed ID: 20516252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased ubiquinone availability and impaired mitochondrial cytochrome oxidase activity associated with statin treatment.
    Duncan AJ; Hargreaves IP; Damian MS; Land JM; Heales SJ
    Toxicol Mech Methods; 2009 Jan; 19(1):44-50. PubMed ID: 19778232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 6-year retrospective study of adverse drug reactions due to drug-drug interactions between nervous system drugs.
    Shi QP; He XD; Yu ML; Zhu JX; Liu Y; Ding F; Sang R; Jiang XD; Zhang SQ
    Int J Clin Pharmacol Ther; 2014 May; 52(5):392-401. PubMed ID: 24691061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.
    Niemi M; Pasanen MK; Neuvonen PJ
    Pharmacol Rev; 2011 Mar; 63(1):157-81. PubMed ID: 21245207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors.
    Takeda M; Noshiro R; Onozato ML; Tojo A; Hasannejad H; Huang XL; Narikawa S; Endou H
    Eur J Pharmacol; 2004 Jan; 483(2-3):133-8. PubMed ID: 14729100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver.
    Sato T; Yamaguchi H; Kogawa T; Abe T; Mano N
    J Pharm Pharm Sci; 2014; 17(4):475-84. PubMed ID: 25579430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of Organic Anion-Transporting Polypeptides, OATP1B1/1B3 and 2B1.
    Patik I; Székely V; Német O; Szepesi Á; Kucsma N; Várady G; Szakács G; Bakos É; Özvegy-Laczka C
    Sci Rep; 2018 Feb; 8(1):2630. PubMed ID: 29422623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
    Smith PF; Eydelloth RS; Grossman SJ; Stubbs RJ; Schwartz MS; Germershausen JI; Vyas KP; Kari PH; MacDonald JS
    J Pharmacol Exp Ther; 1991 Jun; 257(3):1225-35. PubMed ID: 1904494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Drug-induced myopathies].
    Guemara R; Lazarou I; Guerne IA
    Rev Med Suisse; 2017 Mai 10; 13(562):1013-1017. PubMed ID: 28627846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis.
    Koro CE; Sowell MO; Stender M; Qizilbash N
    Clin Ther; 2008 Mar; 30(3):535-42. PubMed ID: 18405791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.